Article
Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.
Gut - 1 Sept 2023
Xu Chang, Huang Kie Kyon, Law Jia Hao, Chua Joy Shijia, Sheng Taotao, Flores Natasha M, Pizzi Melissa Pool, Okabe Atsushi, Tan Angie Lay Keng, Zhu Feng, Kumar Vikrant, Lu Xiaoyin, Benitez Ana Morales, Lian Benedict Shi Xiang, Ma Haoran, Ho Shamaine Wei Ting, Ramnarayanan Kalpana, Anene-Nzelu Chukwuemeka George, Razavi-Mohseni Milad, Abdul Ghani Siti Aishah Binte, Tay Su Ting, Ong Xuewen, Lee Ming Hui, Guo Yu Amanda, Ashktorab Hassan, Smoot Duane, Li Shang, Skanderup Anders Jacobsen, Beer Michael A, Foo Roger Sik Yin, Wong Joel Shi Hao, Sanghvi Kaushal, Yong Wei Peng, Sundar Raghav, Kaneda Atsushi, Prabhakar Shyam, Mazur Pawel Karol, Ajani Jaffer A, Yeoh Khay Guan, So Jimmy Bok-Yan, Tan Patrick
Abstract excerpt
OBJECTIVE: Gastric cancer (GC) is a leading cause of cancer mortality, with ARID1A being the second most frequently mutated driver gene in GC. We sought to decipher ARID1A-specific GC regulatory networks and examine therapeutic vulnerabilities arising from ARID1A loss. DESIGN: Genomic profiling of GC patients including a Singapore cohort (>200 patients) was performed to derive mutational signatures of ARID1A...
Topics
Join the communities discussing this publication.